be a plus sign (+) inside this box + er the Paperwork Reduction Act of 1995, no persons are required to	U. S. Patent and Trade	PTO/SB/08A (08-00) proved for use through 10/31/2002.OMB 0651-0031 prark Office: U.S. DEPARTMENT OF COMMERCE pration unless it contains a valid OMB control number. Complete if Known
Substitute for form 1449A/PTO	Application Alumbay	
`1	Application Number	09/827,688
FORMATION DISCLOSURE	Filing Date	April 6, 2001

e a plus sign (+) inside this box

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of Sheet 1

	Complete if Known					
Application Number	09/827,688					
Filing Date	April 6, 2001					
First Named Inventor	Frank M. Orson					
Group Art Unit	N/A					
Examiner Name	Not Yet Assigned					
Attorney Docket Number	HO-P01949US1					

				U.S. PATENT DOCUMENTS		
	Cito	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevant
	Cite No. ¹	Number	Kind Code ² (if known)	of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
QN		5,703,057		Johnston, Stephen A. et al.	12-30-1997	
QN		5,703,057		Johnston, Stephen A. et al.		

2

				FOREIG	IN PATENT DOCUMENTS	i		
		Foreign Patent Document			-		Pages, Columns, Lines,	[
Examiner Initials*	Cite No. ¹	Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	™
								丄

Examiner Signature	Que Done	Date Considered	10/17/02
			6

*EXAMINER: Initial if reference considered, whether or not elation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-00)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it contains a unit OMB activities.

Pleas	pe a plus sign (+) inside	this box	+ +	Toologia	ark Office: U.S. DEPARTMENT OF COMMERCE ation unless it contains a valid OMB control number
				(Complete if Known
Sut	ostitute for form 1449A/P	то		Application Number	09/827,688
,	NFORMATIO	או חופר	CLOSURE		April 6, 2001
וו	NEORINA NO			First Named Inventor	Frank M. Orson
S	TATEMENT	BYAP	PLICANI	Group Art Unit	N/A
	(use as many	sheets as nec	essary)	Examiner Name	Not Yet Assigned
L					HO-P01949US1
Sheet	2	of		/ morris)	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	Γ.
xaminer	Cite No.1	OTHER PRIOR ART - NON PATENT LITEROS of the appropriate), title of the Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Include name of the Include	T
nitiais	A	Song Li et al. Targeted gene delivery to pulmonary endothelium by anti-PECAW antibody,	
QN	-	Am. J. Physiol. Lun Cell. Mol. Physiol. 200 biotinylation Efficiently Mediates the Endocytosis of	Γ
1	₿,	Wojda, Urszula, et al. Surface Membrane Dibilitylation Ethology 1999. Avidin Bioconjugates into Nucleated Cells; Bioconjugate Chem. 10, 1044-1050, 1999. Avidin Bioconjugates into Nucleated Cells; Bioconjugate Chem. 10, 1044-1050, 1999.	╁
+-	С	Kircheis, R. et al. Coupling of cell-binding liganitis to polycinylorismin and a cell-binding liganitis to be cell-b	L
	D -	delivery; Gene Therapy 4, 409-418, 1997. Erbacher, Patrick et al. Transfection and Physical Properties of Various Saccaride,	1
1	<u> </u>	Poly(ethylene glycol), and Antibody-derivatized Polycury-terminate (\perp
	ļ <u>.</u> —	Biophysic, 1999. Piedrafita, David et al. Protective Immune Responses Induced by Vaccination with an Piedrafita, David et al. Protective Immune Responses Induced by Vaccination with an Piedrafita, David et al. Protective Immune Responses Induced by Vaccination with an Piedrafita, David et al. Protective Immune Responses Induced by Vaccination with an Piedrafita, David et al. Protective Immune Responses Induced by Vaccination with an Induced by Vaccination with a Induced by Vaccination with an Induced by Vaccination with a Induce	
	E	Expression Genomic Library of Leishmania Wajor, The American	
	<u> </u>	Immunologists, 1999.	1
	F _	Manoutcharian, Kareri et al. Flotestati Sec. 131-36; 1998. library immunization; Immunology Letters 62, 131-36; 1998.	+
	G	Tan, Yadi et al. The Inhibitory Role of CPS Human Gene Therapy 10: 2153-2161; 1999.	1
	 	T L = 14-0- 1A/1A/ At al TINA ann RIVA-paseu vacontos. Printiple	1
-		Elsevier Science Ltd. Vaccine 18 705-711, 2000 of DNA Vaccine Influence Immune	1
	1	McCluskie, M. J. et al. Route and Method of Delivery of Drivers of Delivery of	+
	+	Responses in Mice and Non-Human Primates, Molecular Mice with Rapid Proteasome- Wu, Y et al. Deoxyribonucleic Acid Vaccines Encoding Antigens with Rapid Proteasome-	-
l		Dependent Degradation Are Highly Elite and 16043: 1997	4
	<u> </u>		1
		Gene Therapy and Genetic immunization, information Macroaggregated	
	L	Orson, F. M. Genetic Immunization with Lung-Targeting Macroaggregated Polyethyleneimine-Albumin Conjugates Elicits Combined Systemic and Mucosal Immune Polyethyleneimine-Albumin Conjugates Elicits Combined Systemic Albumin Conjugates Elicits Combined Systemic Albumin Conjugates Elicits Combined Systemic Albumin Conjugates Elicits Combined Systemic Confugates Elicit	1
Qn	7	Polyethyleneimine-Albumin Conjugates Elicits Combined 6313-6321; 2000 Responses; The American Association of Immunologists; 6313-6321; 2000	コ

Examiner 0 10	Date Considered	10/17/02
Signature XAAOA NO		ation if not in conformance and not

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached

RECEIVED
AUG 2 4 2001



see Paper #6

PTO/SB/08A (08-00) 2002.OMB 0651-0031 ENT OF COMMERCE

be a plus sign (+) inside this box		+	Approved for use through 10/31/ U. S. Patent and Trademark Office: U.S. DEPARTM	
er the Paperwork Reduction Act of 1995,	no persons an	e required to resp	U. S. Patent and Trademark Office: U.S. DEFACTM pond to a collection of information unless it contains a vali Complete if Known	DECE!

FMP	•			espond to a collection of informa-	ation unless it contains a	did dilina	
Under th	e Paperwork Reduction Act	of 1995,	no persons are required to the	espond to a collection of information	Complete if Known	-RECEIVE	D
Subs	titute for form 1449A/PTO			Application Number	09/827,688		
		ים	CLOSURE		April 6, 2001	 AUG-2-0-2 002	02
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				First Named Inventor	Frank M. Orson		
S	TATEMENIE	3 Y <i>F</i>	APPLICAIN	Group Art Unit	1636	TECH CENTER 1500	/2900
	(use as many sh	eets as	necessary)	Examiner Name	Q. Nguyen		, 200
⊢——-т	,		2	Attorney Docket Number	HO-P01949US		
Sheet	11	of					
			ILS DATE	NT DOCUMENTS		Calumna Lines	

				U.S. PATENT DOCUMENTS		Pages, Columns, Lines, Where Relevant
Examiner Initials*	Cite	U.S. Paten	t Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
Illiuais		Nullioci				

FOREIGN PATENT DOCUMENTS Pages, Columns, Lines.									
Examiner	Cite	Office ³	Foreign Patent Doo.		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	70	
Initials*	No.'	Onice	140,1100					لب	

L		 ·	
		 Date	i l
Examir	ner	 Considered	
Signatu	ıre	 Draw line through cita	ation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

		to place a check mark here if English language Translation is attached. OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS OTHER PRIOR ART - NON PATENT LITERS), title of the article (when appropriate), title of the Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Include name of the author (in CAPITAL LETTERS), title of the page(s), volume-issue number(s),	T2
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate, item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published. Kircheis, R. et al. Coupling of cell-binding ligands to polyethylenimine for targeted gene	+
an	Α	delivery; Gene Therapy (1997) 4, posterin BEI complexes is an important factor for gene	1
an	8	Ogris, M. et al. The size of DNA/transfermit-Li, composition of the size of the	丰
			_
	 		$-\frac{1}{1}$
	+		_
	Ţ		士

	Date Considered	20117 02
Examiner D		
Signature	Down tine through cita	tion if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached